Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Tian Wenzhi | Founder, CEO, Chief Scientific Officer & Chairman of the Board | 3.84M | -- | 1964 |
| Mr. Li Song | VP of R&D and Executive Director | 1.04M | -- | 1985 |
| Dr. Lu Qiying | Senior VP & Chief Medical Officer | -- | -- | 1974 |
| Dr. Xiong Zikai Ph.D. | Senior Vice President | -- | -- | 1980 |
| Dr. Xiaodong Gan | Senior Vice President | -- | -- | 1963 |
| Mr. Zhang Ruliang | Deputy GM & Senior VP | -- | -- | 1984 |
| Ms. Guan Mei | Secretary, Director of the Financing and Investment Strategy Department & Executive Director | -- | -- | 1983 |
| Mr. Kin Wai Li | Joint Company Secretary | -- | -- | 1989 |
IMMUNEONCO-B
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 156
Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People's Republic of China. Its core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; IMM2902 that in Phase I clinical trial for the treatment of HER2-positive and low expressing solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors. The company has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was incorporated in 2015 and is headquartered in Shanghai, China.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available